Indolinone derivatives
US5064852A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 1, 1990 |
| Grant date | Nov 12, 1991 |
| Priority date | — |
| Expiry date | Aug 1, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D209/96
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A series of novel 3-mono(substituted methyl)- and 3,3-di(substituted methyl)-2-oxo-indoline-1-alkanoic acid compounds have been prepared, including their lower alkyl esters and unsubstituted amide derivatives, as well as the base salts of said acids with pharmacologically acceptable cations. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical members include those compounds derived from 2-oxo-indoline-1-acetic acid wherein a 3,4-dichlorobenzyl or 3,4-dichloro-.alpha.-methylbenzyl moiety is substituted at 3-position of the molecule. Preferred member compounds include 3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 5-chloro-3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-methoxy-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-hydroxy-2-oxo-indoline-1-acetic acid and 3-(3,4-dichloro-.alpha.-methylbenzyl)-2-oxo-indoline-1-acetic acid. Methods for preparing these compounds from known starting materials are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.